Chronic supplementation of beta-hydroxy-beta methylbutyrate (HM beta) increases the activity of the GH/IGF-I axis and induces hyperinsulinemia in rats


Autoria(s): GERLINGER-ROMERO, F.; GUIMARAES-FERREIRA, L.; GIANNOCCO, G.; NUNES, M. T.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Objective: Beta-hydroxy-beta-methylbutyrate (HM beta) is a metabolite of leucine widely used for improving sports performance. Although limp is recognized to promote anabolic or anti-catabolic effects on protein metabolism, the impact of its long-term use on skeletal muscle and/or genes that control the skeletal protein balance is not fully known. This study aimed to investigate whether chronic HM beta treatment affects the activity of GH/IGF-I axis and skeletal muscle IGF-I and myostatin mRNA expression. Design: Rats were treated with HK beta (320 mg/kg BW) or vehicle, by gavage, for 4 weeks, and killed by decapitation. Blood was collected for evaluation of serum insulin, glucose and IGF-I concentrations. Samples of pituitary, liver, extensor digitorum longus (EDL) and soleus muscles were collected for total RNA or protein extraction to evaluate the expression of pituitary growth hormone (GH) gene (mRNA and protein), hepatic insulin-like growth factor I (IGF-I) mRNA, skeletal muscle IGF-I and myostatin mRNA by Northern blotting/real time-PCR, or Western blotting. Results: Chronic HM beta treatment increased the content of pituitary GH mRNA and GH, hepatic IGF-I mRNA and serum IGF-I concentration. No changes were detected on skeletal muscle IGF-I and myostatin mRNA expression. However, the HIM-treated rats although normoglycemic, exhibited hyperinsulinemia. Conclusions: The data presented herein extend the body of evidence on the potential role of HM beta-treatment in stimulating GH/IGF-I axis activity. In spite of this effect, HM beta supplementation also induces an apparent insulin resistance state which might limit the beneficial aspects of the former results, at least in rats under normal nutritional status and health conditions. (C) 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Pesquisa e Desenvolvimento (CNPq), Brazil

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

CNPq

Identificador

GROWTH HORMONE & IGF RESEARCH, v.21, n.2, p.57-62, 2011

1096-6374

http://producao.usp.br/handle/BDPI/27927

10.1016/j.ghir.2010.12.006

http://dx.doi.org/10.1016/j.ghir.2010.12.006

Idioma(s)

eng

Publicador

CHURCHILL LIVINGSTONE

Relação

Growth Hormone & Igf Research

Direitos

restrictedAccess

Copyright CHURCHILL LIVINGSTONE

Palavras-Chave #Beta-hydroxy-beta-methylbutyrate #Growth hormone #Insulin-like growth factor I #Myostatin #Insulin #GROWTH-FACTOR-I #SKELETAL-MUSCLE #PROTEIN-METABOLISM #INSULIN-RESISTANCE #GENE-EXPRESSION #AMINO-ACIDS #IGF-I #HORMONE #RECEPTOR #PATHWAYS #Cell Biology #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion